Genprex, Inc. (GNPX): Price and Financial Metrics
GET POWR RATINGS... FREE!
GNPX Stock Price Chart Interactive Chart >
GNPX Price/Volume Stats
| Current price | $1.50 | 52-week high | $4.07 |
| Prev. close | $1.49 | 52-week low | $1.17 |
| Day low | $1.47 | Volume | 115,600 |
| Day high | $1.53 | Avg. volume | 3,923,483 |
| 50-day MA | $1.83 | Dividend yield | N/A |
| 200-day MA | $2.12 | Market Cap | 71.85M |
Genprex, Inc. (GNPX) Company Bio
Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. The company was founded in 2009 and is based in Austin, Texas.
Latest GNPX News From Around the Web
Below are the latest news stories about Genprex Inc that investors may wish to consider to help them evaluate GNPX as an investment opportunity.
How to Profit From Solar EnergyOnce regarded as too expensive and inefficient, solar energy is now becoming a more viable option for both consumers and businesses. |
Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on February 24, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty five |
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and DiabetesAUSTIN, Texas, February 09, 2022--Genprex announces participation in February conferences. |
This Biotech Company Has Cancer and Diabetes Treatments in DevelopmentReal Money''s Timothy Collins says Genprex has persevered in the face of successive setbacks. |
Preclinical study suggests potential use of Genprex ONCOPREX in colon cancerGenprex < |
GNPX Price Returns
| 1-mo | -5.06% |
| 3-mo | -32.74% |
| 6-mo | 0.00% |
| 1-year | -59.89% |
| 3-year | -7.41% |
| 5-year | N/A |
| YTD | 14.50% |
| 2021 | -68.43% |
| 2020 | 1,196.88% |
| 2019 | -70.91% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...